Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus

Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus

<p>Abstract</p> <p>The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and DPP-4 inhibitors act on the incretin sys...

Full description

Bibliographic Details
Main Author: Cobble Michael
Format: Article
Language:English
Published: BMC 2012-03-01
Series:Diabetology & Metabolic Syndrome
Subjects:
type 2 diabetes
exenatide
liraglutide
sitagliptin
saxagliptin
linagliptin
efficacy
safety
Online Access:http://www.dmsjournal.com/content/4/1/8

Internet

http://www.dmsjournal.com/content/4/1/8

Similar Items